Researchers have developed a novel weight-loss drug that combines GLP-1 with molecules targeting NMDA receptors in the brain.

The effect of a low-calorie, sufficient fiber regimen combined with probiotic supplements and physical activity on health, ...

Non-HDL-c is a primary risk factor for cardiovascular disease and a possible target for lipid-lowering drugs. The gut ...

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall ...

Learn more about whether ADMA Biologics Inc or Axsome Therapeutics Inc is a better investment based on AAII's A+ Investor ...

After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 ...

After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination ...

The FDA has granted accelerated approval to tarlatamab (Imdelltra) as a third-line option for patients with extensive-stage ...

After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination ...

Acrochordons, or skin tags, which are common, benign skin growths that appear in the axilla and other areas where frequent ...

The global neurodegenerative disease market size is expected to be valued at USD 52.08 billion by 2024. The market valuation ...